In this Issue
Vol. I · Issue 01
"Most 'this peptide didn't work' reports trace to reconstitution or storage error, not manufacturing. The vial is fine. The handling wasn't."
— Further Reading —
From the Examiner's archive.
14 notes published across 10 research topics, organized by mechanism and procurement question.
HPLC Purity: What the Chromatogram Actually Tells You
A purity percentage with no chromatogram is roughly worthless. Here's how to read the underlying data and what each peak means.
May 9, 2026 · 3 min read
Storage and Reconstitution Best Practices for Research Peptides
Lyophilized peptides are stable. Once reconstituted, the clock starts. A practical reference on what to use, what to avoid, and what kills a vial.
May 8, 2026 · 2 min read
Understanding the GLP-1 Receptor Family
GLP-1, GIP, glucagon — the incretin and glucagon receptors that anchor modern metabolic peptide pharmacology. A primer on the receptor landscape.
May 7, 2026 · 2 min read
Semaglutide vs Tirzepatide: A Side-by-Side Comparison
Both are approved metabolic peptide therapeutics. One is a single-receptor agonist, one activates two receptors. Here's what the research actually shows.
May 6, 2026 · 2 min read
Cagrilintide: The Long-Acting Amylin Analog
A modified amylin analog studied in combination with incretin agonists. Why amylin pharmacology is the underrecognized half of modern metabolic research.
May 5, 2026 · 2 min read
GHK-Cu: A Primer on the Copper Tripeptide
Glycyl-L-histidyl-L-lysine bound to copper(II). Among the most-studied peptide-metal complexes in cosmetic and tissue-research literature.
May 4, 2026 · 1 min read
Ipamorelin: The Cleanest Selective Ghrelin-Receptor Agonist
A pentapeptide GH-releasing peptide that triggers pulsatile GH release without affecting cortisol or prolactin. The selectivity profile that makes it the canonical reference compound.
May 3, 2026 · 1 min read
TB-500: A Reference on the Thymosin Beta-4 Fragment
A 17-amino-acid fragment of one of the most abundant proteins in mammalian cells. Mechanism, half-life, and why it pairs with BPC-157 in tissue-research literature.
May 1, 2026 · 1 min read
Tirzepatide: The Dual Receptor Mechanism Explained
Tirzepatide is the first approved dual GLP-1/GIP receptor agonist. A primer on why dual-incretin pharmacology matters and how the molecule was engineered.
Apr 30, 2026 · 2 min read
What Is BPC-157? A Reference on the Body Protection Compound
A synthetic pentadecapeptide drawn from a sequence in gastric juice. Mechanism, half-life, and why it's one of the most-studied peptides in laboratory tissue-repair research.
Apr 22, 2026 · 1 min read
— Reading by Pathway —
Articles, organized by research axis.
Every Molecular Examiner article maps to one of three peptide-research axes — metabolic, GH-axis, or tissue repair — plus the methodology articles that underwrite all three. The clusters below match the structure of the broader research literature.
— Axis 01 — Metabolic / Incretin
4 notes
— Axis 03 — Tissue Repair
3 notes
— Glossary —
Terms a reader will encounter.
Six representative entries. The full glossary covers fifty-plus terms — analytical techniques, regulatory categories, compound families, receptor classes.
- HPLC
- High-Performance Liquid Chromatography. Standard analytical method for peptide purity at 220 nm.
- Mass spectrometry
- Identity confirmation via molecular weight. MALDI-TOF or ESI-MS appear on every reference COA.
- Counter-ion
- The non-peptide ion accompanying the peptide. TFA or acetate. Affects solubility + assay compatibility.
- Peptide content
- Percentage of gross vial mass that is actual peptide. Typically 70–90%; the rest is counter-ions and water.
- Endotoxin
- Lipopolysaccharide contamination measured in EU/mg. Required reading for cell-culture and animal-model work.
- Lyophilized
- Freeze-dried. Default storage form for research peptides; stable for years at -20°C.
— How articles are produced —
Citation-anchored
Every mechanism claim traces to peer-reviewed literature. Where literature doesn't exist, we say so explicitly.
No medical recommendations
Compounds discussed are research reference standards. No doses, no protocols, no human-use bridges from research findings.
No sponsored content
When we point readers to a supplier, the disclosure is on the page. Affiliate relationships do not change which suppliers we recommend.
— Common Questions —
Before you start reading.
- Who writes Molecular Notes?
- The Molecular Examiner Editorial — a team-edited publication rather than a single named author. We deliberately avoid the fabricated-persona pattern that dominates the peptide-research space online. The editorial-standards page lists what the team does and does not do.
- How are articles sourced?
- Every article traces back to peer-reviewed publication where the underlying literature exists. Where it does not, we say so explicitly. The publication does not run sponsored content. When we point readers to a supplier, the disclosure is on the page.
- Does Molecular Notes recommend doses or treatments?
- No. The compounds discussed are research reference standards, not approved drugs. We do not recommend doses, administration routes, or therapeutic protocols. For medical questions, consult a licensed physician.
— The Editor's Note —
Independent. Sourced. Skeptical.
The Molecular Examiner is the reference we wanted when we started — clear, sourced, and unwilling to bridge research findings into therapeutic recommendations. Articles trace back to peer-reviewed literature where it exists; where it doesn't, we say so.
We don't run sponsored content. When we point readers to a supplier, the disclosure is on the page.
Read our editorial standards →— Subscribe —
A new note, ~monthly.
No filler. Each note takes weeks to research. Subscribe and we'll email you when a new one drops — and the occasional reading list curated by the editors.